Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (vol 22, pg 489, 2021)

被引：0
|
作者：
Rugo, H. S.
Lerebours, F.
Ciruelos, E.
机构：
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E184 / E184
页数：1
相关论文
共 50 条
  • [11] EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).
    De Laurentiis, Michelino
    Costa, Luis
    Gligorov, Joseph
    Knop, Ann
    Senkus-Konefka, Elzbieta
    Garcia-Saenz, Jose A.
    Schmid, Peter
    Heniquez, Aurelia
    Serra, Paolo
    Reising, Albert
    Kuemmel, Sherko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [12] Alpelisib plus endocrine therapy (ET) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
    Juric, Dejan
    Turner, Nicholas
    Prat, Aleix
    Chia, Stephen
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Bachelot, Thomas
    Balbin, O. Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Rugo, Hope S.
    CANCER RESEARCH, 2022, 82 (04)
  • [13] BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibitor therapy
    Rugo, Hope S.
    Turner, Nicholas
    Chia, Stephen
    Ciruelos, Eva
    Nienstedt, Carolyn
    Ridolfi, Antonia
    Kong, Oliver
    Sankaran, Banu
    Juric, Dejan
    CANCER RESEARCH, 2018, 78 (04)
  • [14] Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
    Chia, Stephen
    Ciruelos, Eva M.
    Rugo, Hope S.
    Lerebours, Florence
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Prat, Aleix
    Bachelot, Thomas
    Turner, Nicholas
    Gu, Ennan
    Arce, Christina
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
  • [15] Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.
    Chia, Stephen K. L.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Juric, Dejan
    Bachelot, Thomas
    Rugo, Hope S.
    Ciruelos, Eva M.
    Lerebours, Florence
    Prat, Aleix
    Akdere, Murat
    Arce, Christina
    Gu, Ennan
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [16] Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
    Garrido-Castro, Ana C.
    Graham, Noah
    Ali, Lestat R.
    Herold, Christina
    Desrosiers, Jennifer
    Do, Khanh
    Parsons, Heather
    Li, Tianyu
    Goel, Shom
    Dilullo, Molly
    Wrabel, Eileen
    Williams, Amy J.
    Liu, Joyce F.
    Mittendorf, Elizabeth A.
    Dougan, Stephanie K.
    Tayob, Nabihah
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [17] BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.
    Rugo, Hope S.
    Bianchi, Giulia Valeria
    Chia, Stephen K. L.
    Turner, Nicholas C.
    Juric, Dejan
    Jacot, William
    Borrego, Manuel Ruiz
    Chap, Linnea I.
    Brown-Glaberman, Ursa Abigail
    Nienstedt, Carolyn C.
    Sophos, Nikos
    Ridolfi, Antonia
    Lin, Chinjune
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [18] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
    Cardoso, F.
    Juric, D.
    Lerebours, F.
    Krop, I.
    Borrego, M. Ruiz
    Neven, P.
    Park, Y. H.
    Yardley, D.
    Jhaveri, K.
    Arce, C.
    Gu, E.
    Akdere, M.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S206 - S207
  • [19] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
    Rugo, Hope S.
    Borrego, Manuel Ruiz
    Chia, Stephen K. L.
    Juric, Dejan
    Turner, Nicholas C.
    Drullinsky, Pamela
    Lerebours, Florence
    Bianchi, Giulia Valeria
    Nienstedt, Carolyn C.
    Ridolfi, Antonia
    Thuerigen, Astrid
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [20] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Jan, 10.1038/s41388-022-02585-3, 2023)
    Bello Roufai, D.
    Goncalves, A.
    de la Motte Rouge, T.
    Akla, S.
    Blonz, C.
    Grenier, J.
    Gligorov, J.
    Saghatchian, M.
    Bailleux, C.
    Simon, H.
    Desmoulins, I.
    Tharin, Z.
    Renaud, E.
    Bertho, M.
    Benderra, M-a
    Delaloge, S.
    Robert, L.
    Cottu, P.
    Pierga, J. Y.
    Loirat, D.
    Bertucci, A.
    Renouf, B.
    Bidard, F. C.
    Lerebours, F.
    ONCOGENE, 2023, 42 (17) : 1417 - 1417
12345